A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

NCT06229548 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipemia

Interventions

DRUG: SYH2053
DRUG: Placebo

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.